Stocks to Watch: Sana Biotechnology, Richardson Electronics, Maplebear

Dow Jones
01-08
 

By Connor Hart

 

Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading.

Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading.

Instacart parent Maplebear was selected for inclusion in the S&P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&P SmallCap 600 from the S&P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

January 07, 2025 18:36 ET (23:36 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10